The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Genetic COPD-Global Market Insights and Sales Trends 2024
Synopsis
For some people, their COPD is actually related to a rare genetic condition called alpha1-antitrypsin deficiency, or alpha-1 for short. This condition is sometimes referred to as "genetic COPD," and is caused by a deficiency in a specific protein called alpha1-antitrypsin.
The global Genetic COPD market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Genetic COPD in various end use industries. The expanding demands from the Hospitals, Specialty Clinics, Pharmacies and Others, are propelling Genetic COPD market. Augmentation Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Cystic Fibrosis(CF) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Genetic COPD, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Genetic COPD market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Genetic COPD market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Genetic COPD sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Genetic COPD covered in this report include Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline and CSL Behring, etc.
The global Genetic COPD market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Takeda
LFB Biomedicaments
Abeona Therapeutics
Biogen
Vertex Pharmaceuticals
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Kedrion Group
ProMetic Life Sciences
Global Genetic COPD market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Genetic COPD market, Segment by Type:
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Other
Global Genetic COPD market, by Application
Hospitals
Specialty Clinics
Pharmacies
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Genetic COPD companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
For some people, their COPD is actually related to a rare genetic condition called alpha1-antitrypsin deficiency, or alpha-1 for short. This condition is sometimes referred to as "genetic COPD," and is caused by a deficiency in a specific protein called alpha1-antitrypsin.
The global Genetic COPD market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Genetic COPD in various end use industries. The expanding demands from the Hospitals, Specialty Clinics, Pharmacies and Others, are propelling Genetic COPD market. Augmentation Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Cystic Fibrosis(CF) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Genetic COPD, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Genetic COPD market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Genetic COPD market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Genetic COPD sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Genetic COPD covered in this report include Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline and CSL Behring, etc.
The global Genetic COPD market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Takeda
LFB Biomedicaments
Abeona Therapeutics
Biogen
Vertex Pharmaceuticals
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Kedrion Group
ProMetic Life Sciences
Global Genetic COPD market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Genetic COPD market, Segment by Type:
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Other
Global Genetic COPD market, by Application
Hospitals
Specialty Clinics
Pharmacies
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Genetic COPD companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Genetic COPD
1.1 Genetic COPD Market Overview
1.1.1 Genetic COPD Product Scope
1.1.2 Genetic COPD Market Status and Outlook
1.2 Global Genetic COPD Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Genetic COPD Market Size by Region (2018-2029)
1.4 Global Genetic COPD Historic Market Size by Region (2018-2023)
1.5 Global Genetic COPD Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Genetic COPD Market Size (2018-2029)
1.6.1 North America Genetic COPD Market Size (2018-2029)
1.6.2 Europe Genetic COPD Market Size (2018-2029)
1.6.3 Asia-Pacific Genetic COPD Market Size (2018-2029)
1.6.4 Latin America Genetic COPD Market Size (2018-2029)
1.6.5 Middle East & Africa Genetic COPD Market Size (2018-2029)
2 Genetic COPD Market by Type
2.1 Introduction
2.1.1 Augmentation Therapy
2.1.2 Cystic Fibrosis(CF)
2.1.3 Non-CF Bronchiectasis(NCFB)
2.1.4 Other
2.2 Global Genetic COPD Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Genetic COPD Historic Market Size by Type (2018-2023)
2.2.2 Global Genetic COPD Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Genetic COPD Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Genetic COPD Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Genetic COPD Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Genetic COPD Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Genetic COPD Revenue Breakdown by Type (2018-2029)
3 Genetic COPD Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Specialty Clinics
3.1.3 Pharmacies
3.1.4 Others
3.2 Global Genetic COPD Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Genetic COPD Historic Market Size by Application (2018-2023)
3.2.2 Global Genetic COPD Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Genetic COPD Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Genetic COPD Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Genetic COPD Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Genetic COPD Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Genetic COPD Revenue Breakdown by Application (2018-2029)
4 Genetic COPD Competition Analysis by Players
4.1 Global Genetic COPD Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Genetic COPD as of 2022)
4.3 Date of Key Players Enter into Genetic COPD Market
4.4 Global Top Players Genetic COPD Headquarters and Area Served
4.5 Key Players Genetic COPD Product Solution and Service
4.6 Competitive Status
4.6.1 Genetic COPD Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Genetic COPD Products, Services and Solutions
5.1.4 Pfizer Genetic COPD Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Baxter
5.2.1 Baxter Profile
5.2.2 Baxter Main Business
5.2.3 Baxter Genetic COPD Products, Services and Solutions
5.2.4 Baxter Genetic COPD Revenue (US$ Million) & (2018-2023)
5.2.5 Baxter Recent Developments
5.3 AstraZeneca
5.3.1 AstraZeneca Profile
5.3.2 AstraZeneca Main Business
5.3.3 AstraZeneca Genetic COPD Products, Services and Solutions
5.3.4 AstraZeneca Genetic COPD Revenue (US$ Million) & (2018-2023)
5.3.5 Grifols Recent Developments
5.4 Grifols
5.4.1 Grifols Profile
5.4.2 Grifols Main Business
5.4.3 Grifols Genetic COPD Products, Services and Solutions
5.4.4 Grifols Genetic COPD Revenue (US$ Million) & (2018-2023)
5.4.5 Grifols Recent Developments
5.5 Teva Pharmaceutical Industries
5.5.1 Teva Pharmaceutical Industries Profile
5.5.2 Teva Pharmaceutical Industries Main Business
5.5.3 Teva Pharmaceutical Industries Genetic COPD Products, Services and Solutions
5.5.4 Teva Pharmaceutical Industries Genetic COPD Revenue (US$ Million) & (2018-2023)
5.5.5 Teva Pharmaceutical Industries Recent Developments
5.6 Boehringer Ingelheim
5.6.1 Boehringer Ingelheim Profile
5.6.2 Boehringer Ingelheim Main Business
5.6.3 Boehringer Ingelheim Genetic COPD Products, Services and Solutions
5.6.4 Boehringer Ingelheim Genetic COPD Revenue (US$ Million) & (2018-2023)
5.6.5 Boehringer Ingelheim Recent Developments
5.7 Kamada Ltd
5.7.1 Kamada Ltd Profile
5.7.2 Kamada Ltd Main Business
5.7.3 Kamada Ltd Genetic COPD Products, Services and Solutions
5.7.4 Kamada Ltd Genetic COPD Revenue (US$ Million) & (2018-2023)
5.7.5 Kamada Ltd Recent Developments
5.8 GlaxoSmithKline
5.8.1 GlaxoSmithKline Profile
5.8.2 GlaxoSmithKline Main Business
5.8.3 GlaxoSmithKline Genetic COPD Products, Services and Solutions
5.8.4 GlaxoSmithKline Genetic COPD Revenue (US$ Million) & (2018-2023)
5.8.5 GlaxoSmithKline Recent Developments
5.9 CSL Behring
5.9.1 CSL Behring Profile
5.9.2 CSL Behring Main Business
5.9.3 CSL Behring Genetic COPD Products, Services and Solutions
5.9.4 CSL Behring Genetic COPD Revenue (US$ Million) & (2018-2023)
5.9.5 CSL Behring Recent Developments
5.10 Takeda
5.10.1 Takeda Profile
5.10.2 Takeda Main Business
5.10.3 Takeda Genetic COPD Products, Services and Solutions
5.10.4 Takeda Genetic COPD Revenue (US$ Million) & (2018-2023)
5.10.5 Takeda Recent Developments
5.11 LFB Biomedicaments
5.11.1 LFB Biomedicaments Profile
5.11.2 LFB Biomedicaments Main Business
5.11.3 LFB Biomedicaments Genetic COPD Products, Services and Solutions
5.11.4 LFB Biomedicaments Genetic COPD Revenue (US$ Million) & (2018-2023)
5.11.5 LFB Biomedicaments Recent Developments
5.12 Abeona Therapeutics
5.12.1 Abeona Therapeutics Profile
5.12.2 Abeona Therapeutics Main Business
5.12.3 Abeona Therapeutics Genetic COPD Products, Services and Solutions
5.12.4 Abeona Therapeutics Genetic COPD Revenue (US$ Million) & (2018-2023)
5.12.5 Abeona Therapeutics Recent Developments
5.13 Biogen
5.13.1 Biogen Profile
5.13.2 Biogen Main Business
5.13.3 Biogen Genetic COPD Products, Services and Solutions
5.13.4 Biogen Genetic COPD Revenue (US$ Million) & (2018-2023)
5.13.5 Biogen Recent Developments
5.14 Vertex Pharmaceuticals
5.14.1 Vertex Pharmaceuticals Profile
5.14.2 Vertex Pharmaceuticals Main Business
5.14.3 Vertex Pharmaceuticals Genetic COPD Products, Services and Solutions
5.14.4 Vertex Pharmaceuticals Genetic COPD Revenue (US$ Million) & (2018-2023)
5.14.5 Vertex Pharmaceuticals Recent Developments
5.15 Baxalta
5.15.1 Baxalta Profile
5.15.2 Baxalta Main Business
5.15.3 Baxalta Genetic COPD Products, Services and Solutions
5.15.4 Baxalta Genetic COPD Revenue (US$ Million) & (2018-2023)
5.15.5 Baxalta Recent Developments
5.16 Arrowhead Research Corporation
5.16.1 Arrowhead Research Corporation Profile
5.16.2 Arrowhead Research Corporation Main Business
5.16.3 Arrowhead Research Corporation Genetic COPD Products, Services and Solutions
5.16.4 Arrowhead Research Corporation Genetic COPD Revenue (US$ Million) & (2018-2023)
5.16.5 Arrowhead Research Corporation Recent Developments
5.17 ProBioGen
5.17.1 ProBioGen Profile
5.17.2 ProBioGen Main Business
5.17.3 ProBioGen Genetic COPD Products, Services and Solutions
5.17.4 ProBioGen Genetic COPD Revenue (US$ Million) & (2018-2023)
5.17.5 ProBioGen Recent Developments
5.18 Chiesi Pharmaceuticals
5.18.1 Chiesi Pharmaceuticals Profile
5.18.2 Chiesi Pharmaceuticals Main Business
5.18.3 Chiesi Pharmaceuticals Genetic COPD Products, Services and Solutions
5.18.4 Chiesi Pharmaceuticals Genetic COPD Revenue (US$ Million) & (2018-2023)
5.18.5 Chiesi Pharmaceuticals Recent Developments
5.19 Kedrion Group
5.19.1 Kedrion Group Profile
5.19.2 Kedrion Group Main Business
5.19.3 Kedrion Group Genetic COPD Products, Services and Solutions
5.19.4 Kedrion Group Genetic COPD Revenue (US$ Million) & (2018-2023)
5.19.5 Kedrion Group Recent Developments
5.20 ProMetic Life Sciences
5.20.1 ProMetic Life Sciences Profile
5.20.2 ProMetic Life Sciences Main Business
5.20.3 ProMetic Life Sciences Genetic COPD Products, Services and Solutions
5.20.4 ProMetic Life Sciences Genetic COPD Revenue (US$ Million) & (2018-2023)
5.20.5 ProMetic Life Sciences Recent Developments
6 North America
6.1 North America Genetic COPD Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Genetic COPD Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Genetic COPD Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Genetic COPD Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Genetic COPD Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Genetic COPD Market Dynamics
11.1 Genetic COPD Industry Trends
11.2 Genetic COPD Market Drivers
11.3 Genetic COPD Market Challenges
11.4 Genetic COPD Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
